Immunocore (IMCR) Revenue & Revenue Breakdown
Immunocore Revenue Highlights
Latest Revenue (Y)
$249.43M
Latest Revenue (Q)
$75.40M
Main Segment (Y)
Product Revenue
Main Geography (Y)
UNITED STATES
Immunocore Revenue by Period
Immunocore Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $249.43M | 73.53% |
| 2022-12-31 | $143.74M | 441.99% |
| 2021-12-31 | $26.52M | -11.93% |
| 2020-12-31 | $30.11M | 17.32% |
| 2019-12-31 | $25.67M | 8.52% |
| 2018-12-31 | $23.65M | - |
Immunocore generated $249.43M in revenue during NA 2023, up 73.53% compared to the previous quarter, and up 1054.49% compared to the same period a year ago.
Immunocore Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $75.40M | 6.95% |
| 2024-03-31 | $70.50M | -33.26% |
| 2023-12-31 | $105.64M | 105.16% |
| 2023-09-30 | $51.49M | 7.80% |
| 2023-06-30 | $47.76M | 7.24% |
| 2023-03-31 | $44.54M | -7.33% |
| 2022-12-31 | $48.06M | 16.66% |
| 2022-09-30 | $41.20M | 28.74% |
| 2022-06-30 | $32.00M | 42.40% |
| 2022-03-31 | $22.47M | 240.88% |
| 2021-12-31 | $6.59M | 11.29% |
| 2021-09-30 | $5.92M | 3.33% |
| 2021-06-30 | $5.73M | -30.68% |
| 2021-03-31 | $8.27M | 11.46% |
| 2020-12-31 | $7.42M | 11.55% |
| 2020-09-30 | $6.65M | -14.58% |
| 2020-06-30 | $7.79M | -5.67% |
| 2020-03-31 | $8.26M | 46.31% |
| 2019-12-31 | $5.64M | - |
Immunocore generated $75.40M in revenue during Q2 2024, up 6.95% compared to the previous quarter, and up 169.28% compared to the same period a year ago.
Immunocore Revenue Breakdown
Immunocore Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Product Revenue | $238.74M | - | - | - |
| Genentech | - | $2.48M | $17.43M | $20.24M |
| Eli Lilly | - | - | - | $3.52M |
| GlaxoSmithKline | - | - | $6.08M | $6.36M |
| Med Immune | - | - | - | - |
Immunocore's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 |
|---|---|
| Collaboration Revenue | $160.00K |
| Product Revenue | $70.34M |
Immunocore's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product Revenue (99.77%), and Collaboration Revenue (0.23%).
Immunocore Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Rest of World | $3.60M | $871.00K | - | - |
| UNITED STATES | $169.79M | - | - | - |
| Europe | $67.63M | $35.49M | $3.01M | - |
| United States | - | $80.45M | $17.43M | $23.76M |
| UK | - | - | $6.08M | $6.36M |
Immunocore's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (70.45%), Europe (28.06%), and Rest of World (1.49%).
Quarterly Revenue by Country
| Country | Mar 24 |
|---|---|
| Europe | $18.95M |
| UNITED STATES | $50.03M |
| Rest of World | $1.36M |
Immunocore's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (71.12%), Europe (26.94%), and Rest of World (1.94%).
Immunocore Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMCR | Immunocore | $249.43M | $75.40M |
| MIRM | Mirum Pharmaceuticals | $186.37M | $69.22M |
| ACLX | Arcellx | $110.32M | $27.38M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| DSGN | Design Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| ERAS | Erasca | - | - |
| VTYX | Ventyx Biosciences | - | - |
| LRMR | Larimar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| KALV | KalVista Pharmaceuticals | - | - |
IMCR Revenue FAQ
What is Immunocore’s yearly revenue?
Immunocore's yearly revenue for 2023 was $249.43M, representing an increase of 73.53% compared to 2022. The company's yearly revenue for 2022 was $143.74M, representing an increase of 441.99% compared to 2021. IMCR's yearly revenue for 2021 was $26.52M, representing a decrease of -11.93% compared to 2020.
What is Immunocore’s quarterly revenue?
Immunocore's quarterly revenue for Q2 2024 was $75.4M, a 6.95% increase from the previous quarter (Q1 2024), and a 57.86% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $70.5M, a -33.26% decrease from the previous quarter (Q4 2023), and a 58.29% increase year-over-year (Q1 2023). IMCR's quarterly revenue for Q4 2023 was $105.64M, a 105.16% increase from the previous quarter (Q3 2023), and a 119.79% increase year-over-year (Q4 2022).
What is Immunocore’s revenue growth rate?
Immunocore's revenue growth rate for the last 3 years (2021-2023) was 840.53%, and for the last 5 years (2019-2023) was 871.71%.
What are Immunocore’s revenue streams?
Immunocore's revenue streams in c 23 are Product Revenue
What is Immunocore’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Immunocore was Product Revenue. This segment made a revenue of $238.74M, representing 100.00% of the company's total revenue.